Clinical and early biochemical responses to botulinum toxin type-A in refractory masticatory myofascial pain: a pilot single-arm study
Open Access
- 30 April 2026
- journal article
- research article
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Abstract
Masticatory myofascial pain (MMP) is a common subtype of temporomandibular disorders (TMD) characterized by muscle tenderness and pain during jaw function.Keywords
This publication has 62 references indexed in Scilit:
- Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapiesHeliyon, 2025
- Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic ReviewsDrugs, 2024
- Evaluation of periodontal status and cytokine levels in saliva and gingival crevicular fluid of patients with inflammatory bowel diseasesJournal of Periodontology, 2022
- Myofascial pain in temporomandibular disorders: Updates on etiopathogenesis and managementJournal of Bodywork and Movement Therapies, 2021
- Cytokines, Masticatory Muscle Inflammation, and Pain: an UpdateJournal of Molecular Neuroscience, 2020
- Roles of inflammation, neurogenic inflammation, and neuroinflammation in painJournal of Anesthesia, 2018
- Masticatory Muscle Pain Biomarkers2017
- A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: Role of CGRP in orofacial painExperimental Neurology, 2015
- Association of antinociceptive action of botulinum toxin type A with GABA-A receptorJournal of Neural Transmission, 2014
- Calcitonin gene-related peptide-like immunoreactivity, in botulinum toxin-paralysed rat musclesNeuromuscular Disorders, 1994